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Recent	evidence	suggests	that	the	heart	possesses	a	greater	regeneration	capacity	than	previously	thought.	In	
the	present	study,	we	isolated	undifferentiated	precursors	from	the	cardiac	nonmyocyte	cell	population	of	
neonatal	hearts,	expanded	them	in	culture,	and	induced	them	to	differentiate	into	functional	cardiomyocytes.	
These	cardiac	precursors	appear	to	express	stem	cell	antigen–1	and	demonstrate	characteristics	of	multipotent	
precursors	of	mesodermal	origin.	Following	infusion	into	normal	recipients,	these	cells	home	to	the	heart	
and	participate	in	physiological	and	pathophysiological	cardiac	remodeling.	Cardiogenic	differentiation	in	
vitro	and	in	vivo	depends	on	FGF-2.	Interestingly,	this	factor	does	not	control	the	number	of	precursors	but	
regulates	the	differentiation	process.	These	findings	suggest	that,	besides	its	angiogenic	actions,	FGF-2	could	
be	used	in	vivo	to	facilitate	the	mobilization	and	differentiation	of	resident	cardiac	precursors	in	the	treatment	
of	cardiac	diseases.
Introduction
Cardiac diseases, in particular heart failure, are major causes of 
mortality and morbidity (1, 2). Current therapies do not address 
adequately the loss of contractile tissues in the diseased heart. This 
damage accounts for a large part of the deterioration of cardiac 
functions. On the other hand, recent lines of evidence suggest that 
the heart demonstrates a greater degree of regeneration than pre-
viously thought. This is supported by observations indicating that 
cardiomyocytes could be replaced continually in the heart through 
a process involving cellular aging, senescence, and death as well as 
myocardial cell replication (3). Although this alternative view chal-
lenges the strong belief that cardiomyocytes are terminally differ-
entiated cells that do not divide, it has been fueled by the discovery, 
in many adult organs, of pluripotent progenitors with a capacity to 
differentiate into a variety of cell types (4, 5).
Indeed, cardiomyocytes can be produced in vitro and in vivo 
from adult pluripotent cells. For example, HSCs or endothelial 
progenitor cells demonstrate an ability to differentiate into car-
diomyocytes (6–9). However, whether or not stem cells from 
peripheral origin can represent a valuable source of progenitors for 
replacement therapy in cardiac diseases remains to be established. 
In reality, the rate of commitment to the cardiogenic lineage after 
adoptive transfer in vivo is low, and the exact contribution of cell 
fusion in the engraftment process needs to be clarified (10–14). 
Therefore, an alternative approach to inducing cardiac healing 
would consist in the mobilization and differentiation of resident 
stem cells in the heart. However, to insure a tight control of these 
signaling events, we need to carefully identify the humoral factors 
that are released from the cardiac microenvironment, and which 
might regulate the fate and cardiogenic conversion of undifferen-
tiated progenitors (15).
Among others, FGF-2 has been implicated in cell proliferation, 
survival, and differentiation (16, 17). It is a member of the family 
of heparin-binding growth factors that bind tyrosine kinase recep-
tors. In the heart, FGF-2 expression was shown to be upregulated 
after cardiac injury, such as ischemia/reperfusion, or in the process 
of cardiac remodeling (18). Along these lines, this factor has been 
reported to confer cardioprotection in a variety of animal models 
(19–21) and has been shown to be beneficial for treating ischemic 
conditions in several clinical trials (22–25). It is also important to 
note that FGF-2 plays a role in driving mesodermal cells to the 
cardiogenic lineage during embryogenesis (26–28). Finally, FGF-2 
was shown to be critical for the proliferation of the hemangio-
blast, the common progenitor of hematopoietic and endothelial 
cells (29–31). Therefore, in an attempt to assess the capacity of 
the heart to produce newly formed myocytes, which could be 
activated and recruited for cardiac repair, we initiated a series of 
experiments aimed at isolating undifferentiated cardiac precursors 
from the neonatal and the adult heart. Second, we established the 
conditions for the expansion and differentiation of these cells in 
vitro and in vivo. And finally, we focused our attention on signals 
provided by FGF-2.
Results
Identification, isolation, and differentiation of cardiac precursors. In many 
organ systems, precursor cells have been identified based on the 
expression of stem cell antigen–1 (Sca-1). In the neonatal heart of 
WT mice, Sca-1+ cells were readily detected by immunostaining 
(Figure 1A). In the adult, Sca-1 expression was also observed, and 
associated with a nonmyocyte population (Figure 1, A and B). 
Moreover, in the adult, Sca-1 was overexpressed during compensa-
tory cardiac hypertrophy that developed secondary to renovascular 
hypertension (2-kidney 1-clip model; ref. 32).
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Neonatal hearts were then isolated, and a cardiac single-cell sus-
pension was obtained using enzymatic digestion. Approximately 
10% of the whole cardiac population expressed Sca-1 (Figure 1C, 
Total). These cells were further separated into cardiomyocyte and 
nonmyocyte cell (NMC) fractions. The percentage of cells express-
ing the stem cell marker in these different fractions was equivalent 
to that observed in the starting population (Figure 1C). Further-
more, about 2–3% of the cells were positive for c-kit expression. 
Double-positive cells represented only 0.5% of NMCs (data not 
shown). As compared with the neonatal heart, a greater number 
of adult cardiac NMCs expressed Sca-1. Indeed, 65% of the NMC 
population were positive for Sca-1 expression (Figure 1D). How-
ever, because several cell types were known to express Sca-1, we next 
isolated a Lin– NMC population depleted of cells expressing CD45, 
CD31, CD34, Flk-1, CD3, CD4, CD8, B220, TER119, Mac-1, and 
Gr-1. In this case, the fraction of Sca-1+ cells within the adult NMC 
population was drastically reduced to 33%. Interestingly, the per-
centage of neonatal NMCs expressing Sca-1 was not significantly 
changed following depletion (11% ± 3% vs. 7% ± 1% in undepleted 
and depleted neonatal NMCs, respectively; Figure 1D).
In an attempt to expand a population of potential cardiac pre-
cursors, neonatal NMCs were cultured in vitro. After 2 passages, 
the expression of lineage-specific markers was analyzed by RT-PCR, 
immunohistochemistry, and flow cytometry (Figure 2). WT neo-
natal NMCs did not show significant expression of endothelial or 
hematopoietic cell markers, including CD31, Flk-1, CD45, CD34, 
TER119, Mac-1, Gr-1, and CD3 (Figure 2A). In addition, these cells 
did not express cardiac-specific proteins such as Nkx2.5, GATA-4, 
myosin light chain–2v (MLC-2v), troponin I, and cardiac actin 
(Figure 2B). In contrast, expanded NMCs expressed Sca-1, c-kit, 
and the transcription factors islet-1 and Snail, as well as E-, VE-, 
and N-cadherins (Figure 2, B and C). The number of Sca-1+ NMCs 
appeared to increase significantly during the expansion in culture 
(compare the percentage of neonatal Sca-1+ NMCs in Figure 1D, 
11% ± 3%, with that in Figure 2A, 30% ± 6%), whereas the fraction of 
cells expressing c-kit did not seem to change. Sca-1+ troponin– cells 
were small and presented a round shape that differed from that of 
cardiomyocytes (see Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI23418DS1). 
Interestingly, the percentages of adult NMCs expressing Sca-1 and 
c-kit following expansion in vitro (Figure 2A) were dramatically 
smaller than that observed immediately after isolation (Figure 1D) 
or in the corresponding neonatal population (Figure 2A).
Since neonatal NMCs demonstrated a capacity to be expanded 
in vitro as compared with adult NMCs, we assessed the capac-
ity of these cells to differentiate into functional cardiomyocytes. 
Figure 1
Sca-1 expression in cardiac tissues from 
WT (FGF-2+/+) or FGF-2–deficient (FGF-2–/–) 
mice. (A) Sca-1 immunostaining in heart sec-
tions from FGF-2+/+ and FGF-2–/– neonatal and 
adult mice with or without renovascular hyper-
tension and cardiac hypertrophy (2-kidney 
1-clip model [2K1C]). Original magnification, 
×20 and ×63 (insets). (B) Immunodetection 
of Sca-1 and troponin I in the hearts of adult 
FGF-2+/+ mice. Original magnification, ×40 (left 
panels), ×63 (right panels). (C) Percentage of 
Sca-1+ and c-kit+ cells as determined by FACS 
analysis in total heart cells (Total) and in the 
cardiomyocyte (CM) and nonmyocyte cell 
(NMC) fractions from FGF-2+/+ and FGF-2–/– 
mice (n = 5). (D) Percentage of Sca-1+ cells 
as determined by FACS analysis in neonatal 
or adult NMCs isolated from FGF-2+/+ (white 
bars) and FGF-2–/– mice (black bars). NMCs 
were either depleted or not depleted of cells 
expressing CD45, CD31, CD34, Flk-1, CD3, 
CD4, CD8, B220, TER119, Mac-1, and Gr-1. 
*P < 0.05; NS, not significant as compared 
with the corresponding nondepleted group; 
n = 3–6.
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A variety of media were tested for the ability to sustain cardio-
genic differentiation as judged by the appearance of cells dem-
onstrating sarcomeric rearrangements (Supplemental Figure 2), 
and also spontaneous beatings. The medium referred to as differ-
entiation medium in this article was the most potent in this assay 
(data not shown). Therefore, we determined whether precursor 
cells giving rise to functional cardiomyocytes expressed Sca-1. For 
this purpose, we followed the fate of Sca-1+ cells during the dif-
ferentiation process. Figure 3, A–L, depicts the different cell types 
that were detected in the culture. During the first days, Sca-1+ 
cells were essentially troponin– (Figure 3, A–C). Once again, at this 
point, the morphology of Sca-1+ troponin– cells differed markedly 
from that of cardiomyocytes. At a later stage, double-positive cells, 
i.e., Sca-1+ troponin+ cells, represented the majority of the cells, 
although some cells were still single-positive for Sca-1 (Figure 3, 
D–F). Lastly, mature cardiomyocytes, which expressed only car-
diac markers, were detected in more advanced cultures (Figure 3, 
G–I). Moreover, the expression in differentiating cells of early and 
late cardiac markers such as Nkx2.5, GATA-4, MEF-2c, MLC-2a, 
MLC-2v, troponin I, and cardiac actin was evident at 1 and 3 weeks 
after placement of expanded NMCs in differentia-
tion medium (Figure 4A). Three weeks after the 
initiation of differentiation, approximately 5% 
of the cells in the culture showed a phenotype of 
mature cardiomyocytes (Figure 4B). In addition, 
spontaneous contractions were easily detected in 
the culture as early as 3 days after placement of 
the cells in differentiation medium. Interestingly, 
the differentiating cells often grew in clusters and 
demonstrated synchronized beatings. In parallel 
experiments, we evaluated the requirement for 
c-kit signaling during the differentiation of 
NMCs into cardiomyocytes using precursor cells 
isolated from mice with reduced c-kit signaling 
(W/Wv mutants; refs. 33, 34). Interestingly, full 
activation of c-kit was not mandatory for the car-
diac precursor population to produce functional 
cardiomyocytes, since NMCs from mutant mice 
gave rise to spontaneously beating cells expressing 
cardiac markers (Supplemental Figure 3).
We also evaluated the multipotent capacity 
of the NMC precursors. Our attempts to clone 
these precursors were unsuccessful. Therefore, 
the whole NMC population after expansion in vitro was plated 
in various media that were selected for their ability to sustain 
the differentiation into specific cell types. Under the appropriate 
conditions, NMCs produced adipocytes, skeletal myocytes, and 
osteoblasts, which were detected in the different cultures using 
specific staining and amplification of defined molecular markers 
(Figure 5). Finally, it is noteworthy that the presence of progeni-
tors was also detected in NMC cultures based on Snail and islet-1 
expression (Figure 2C).
Cardiogenic differentiation of cardiac progenitors is dependent on FGF-2. 
The capacity of cardiac precursors to be recruited for cardiac repair 
and to differentiate into fully functional myocytes depends on fac-
tors provided by the surrounding tissues. After expansion in vitro 
and before differentiation, the expression of FGF-2, FGF-1, bone 
morphogenetic protein–2 (BMP-2), BMP-4, TGF-β1, and TGF-β2 
was easily detected in cardiac NMCs (Figure 6). FGF-4 and FGF-10 
expression was barely detected, whereas FGF-8 did not seem to be 
expressed. Moreover, FGF-2 expression was absent in control undif-
ferentiated culture as compared with what was seen in differentiation 
medium, in which FGF-2 and its cognate receptor (FGFR1) appeared 
Figure 2
Characterization of the NMC population before differ-
entiation. (A) Quantification by FACS analysis of neo-
natal and adult NMCs from FGF-2+/+ (white bars) and 
FGF-2–/– mice (black bars) expressing CD31, Flk-1, 
CD45, CD34, TER119, Mac-1, Gr-1, CD3, Sca-1, and 
c-kit after expansion in vitro (n = 5–12). (B) RT-PCR 
analysis of cardiac-specific gene expression as well 
as Sca-1, c-kit, and islet-1 in NMCs after expansion 
and before differentiation (BD), in neonatal cardio-
myocytes (Neo CM) and in the adult heart (Ad heart) 
from either FGF-2+/+ or FGF-2–/– mice. C-actin, car-
diac actin. (C) RT-PCR analysis of Snail and cadherin 
expression in expanded NMCs (BD), as well as in the 
neonatal (Neo heart) and adult hearts (Ad heart) from 
FGF-2+/+ or FGF-2–/– mice.
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largely upregulated. We therefore initiated a series of experiments 
aimed at assessing the role of FGF-2 in the maintenance, the recruit-
ment, and the differentiation of cardiac precursors.
First, the presence of Sca-1+ cells in the heart of neonatal and 
adult FGF-2 knockouts was investigated. In neonates, cardiac Sca-1 
expression did not differ from that of WTs (Figure 1, A and C). In 
contrast, Sca-1 staining in the heart of adult mice lacking FGF-2 
was weaker than that observed in normal littermates (Figure 1A). 
Nevertheless, Sca-1 expression in the heart was upregulated in 
hypertensive mice with cardiac hemodynamic overload. Moreover, 
a significant percentage of adult NMCs lacking FGF-2 expressed 
Sca-1. However, the majority of these cells coexpressed lineage-spe-
cific markers (CD45, CD31, CD34, Flk-1, CD3, CD4, CD8, B220, 
TER119, Mac-1, and Gr-1) as shown by the decrease in percentage 
following depletion of lineage-committed cells (Figure 1D).
Next, the importance of FGF-2 in the differentia-
tion capacity of cardiac precursors was evaluated in 
vitro using NMCs isolated from the neonatal heart 
of mice lacking FGF-2 expression. Immediately fol-
lowing isolation, the number of Sca-1+ cells in the 
cardiac myocyte and nonmyocyte fractions of neo-
natal FGF-2 knockouts was similar to that found in 
WT animals (Figure 1C). After expansion in vitro, 
Sca-1+ cells were also found in NMCs from FGF-2 
knockouts (Supplemental Figure 1). The nonmyo-
cyte population lacking FGF-2 demonstrated even a 
greater percentage of Sca-1+ cells than that observed 
in WT controls (30% ± 6% vs. 48% ± 5% in WTs and 
FGF-2 knockouts, respectively) (Figure 2A). Contrary 
to what we observed in WT NMCs, Nkx2.5 expres-
sion was detected in the FGF-2–deficient nonmyo-
cyte fraction before induction of differentiation (Fig-
ure 2B). Interestingly, this population contained also 
a significant proportion of cells expressing CD34, 
Flk-1, and CD31 (17% ± 3%, 7% ± 4%, and 11% ± 2%, 
respectively; Figure 2A).
The capacity of FGF-2–deficient cells to produce 
cardiac myocytes was then tested. As shown in Fig-
ures 3 and 4, these cells, and specifically Sca-1+ 
cells, failed to develop into functional cardiomyo-
cytes, and no spontaneously contracting cells were 
observed in the culture. Accordingly, after 3 weeks 
in differentiation medium, expression of late car-
diac markers in cells lacking FGF-2 was essentially 
absent (Figure 3, M–O, and Figure 4A). To evaluate 
whether the NMC population in FGF-2 knockouts 
was devoid of cardiac precursors or whether these 
precursors were stopped in their cardiogenic dif-
ferentiation pathway because of a lack of signals, 
exogenous FGF-2 was added to the culture (Figure 3, P–R, and 
Figure 4C). The addition of FGF-2 to cultures of NMCs lack-
ing FGF-2 induced the reappearance of cells that express mark-
ers of mature cardiac myocytes (Figure 3, P–R, and Figure 4C). 
Moreover, in this case, cells expressing both Sca-1 and troponin I 
were readily detected in the culture (Figure 3, P–R), and spon-
taneously beating cells were also evident in this case. In control 
experiments, we evaluated the potential of FGF-1 to support the 
production of cardiomyocytes by FGF-2–deficient NMCs. In 
these experiments, FGF-1 was unable to replace FGF-2 (Figure 
4C). Finally, the possibility that the absence of FGF-2 resulted 
in an increased susceptibility of FGF-2–deficient NMCs to apop-
tosis was investigated. NMCs from neonatal FGF-2 knockouts, 
maintained in control or differentiation medium, demonstrat-
ed a small number of apoptotic cells, which was similar to that 
Figure 3
Cardiogenic differentiation of Sca-1+ cells in vitro. (A–L) 
Immunodetection of Sca-1 and troponin I in differentiating 
NMCs isolated from FGF-2+/+ mice in the absence (None) 
or presence of FGF-2 and maintained for 1 (A–C), 2 
(D–F), or 3 weeks (G–I) in differentiation medium. (M–R) 
The same experiment using NMCs isolated from FGF-2–/– 
mice maintained for 3 weeks in differentiation medium. 
Original magnification, ×40.
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observed in WT cultures (Supplemental Figure 4). Specifically, 
percentages of apoptotic cells in UV-irradiated cultured cells 
(positive control), in cells maintained in control medium, and in 
cells maintained in differentiation medium were 10.5% ± 2.5%, 
2.3% ± 1.2%, and 3.2% ± 1.5%, respectively, for WT NMCs, and 
11.3% ± 1.5%, 2.7% ± 0.9%, and 2.9% ± 1.2%, respectively, for 
FGF-2–deficient NMCs.
Homing capacity of cardiac precursors in vivo. To evaluate the abil-
ity of cardiac precursors to home to the heart, we performed cell 
transfer experiments. In a first series of experiments, the cells were 
injected into neonatal mice to evaluate their potential to contrib-
ute to the physiological postnatal remodeling of the heart. There-
fore, WT NMCs were labeled with the membrane dye PKH2-GL, 
and infused i.v. into recipient mice. In parallel experiments, NMCs 
expressing a GFP transgene under control of the chicken β-actin 
promoter were used. Figure 7A demonstrates that the cells were 
found in cardiac tissues 10 days after infusion, and that these 
cells presented characteristics of differentiated cardiomyocytes. In 
particular, PKH2-GL–labeled and GFP-expressing cells expressed 
α-actinin. Some fluorescent cells were also detected in the 
liver and in skeletal muscles. However, the injected cells 
did not differentiate into the respective tissue (data not 
shown). Interestingly, fluorescence-activated cell sort-
ing–selected (FACS-selected) Sca-1+ cells had a greater 
potential for engraftment as compared with Sca-1– cells 
(percentages of successful transfers were 100% vs. 40% in 
recipients having received FACS-purified Sca-1+ and Sca-1– 
cells, respectively; n = 4–5 mice per group).
We next performed a series of experiments aimed at 
assessing the need for FGF-2 in the engraftment and dif-
ferentiation processes in vivo. Therefore, WT NMCs as 
well as NMCs lacking FGF-2 expression were injected into 
either WT or FGF-2–deficient neonates (Figure 7B). Hom-
ing was observed in all groups regardless of the capacity 
of the recipients or the injected cells to synthesize FGF-2. How-
ever, differentiation in situ was only seen if either the recipient 
animal or the injected cells were able to produce FGF-2. Indeed, 
no differentiation was observed in FGF-2–deficient mice receiv-
ing NMCs lacking FGF-2 expression. The success rate of homing 
Figure 4
Differentiation of cardiac precursors into functional cardiomy-
ocytes. (A) RT-PCR analysis of cardiac-specific gene expres-
sion in NMCs from FGF-2+/+ or FGF-2–/– mice maintained in 
control (C) or differentiation medium (D) in the absence of 
FGF-2 (None), after 1 week or 3 weeks in culture. (B) Quantifi-
cation of troponin I+ cells and spontaneously contracting cells 
in culture of differentiated cardiac precursor from FGF-2+/+ 
and FGF-2–/– mice after 3 weeks in control medium (white 
bars) or differentiation medium (black bars); n = 6–10. 
*P < 0.05. (C) RT-PCR analysis of cardiac-specific gene 
expression in NMCs from FGF-2+/+ or FGF-2–/– mice main-
tained in control or differentiation medium in the presence of 
FGF-2 or FGF-1 after 1 week or 3 weeks in culture.
Figure 5
Multipotent capacity of cardiac precursors. (A) Oil red staining and 
RT-PCR analysis of PPARγ and lipoprotein lipase (LPL) expres-
sion in cultures of NMCs induced to differentiate into adipocytes. 
(B) Immunodetection of MyoD1 and RT-PCR analysis of MyoD1 
expression in cultures of NMCs induced to differentiate into skel-
etal myoblasts. (C) Immunodetection of osteocalcin and RT-PCR 
analysis of osteocalcin expression in cultures of NMCs induced to 
differentiate into osteoblasts. Original magnification, ×20 (A and C), 
×30 (C, inset), ×40 (B), ×63 (B, inset). 
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following NMC injections was also reduced in this latter case. Spe-
cifically, whereas 100% of the transferred animals demonstrated 
engraftment when FGF-2 was produced by either the recipient or 
the injected cells, only 40% of FGF-2 knockouts having received 
NMCs lacking FGF-2 demonstrated significant homing (n = 9–12). 
Finally, to exclude that cardiac precursors contribute to cardiac 
morphogenesis via cell fusion, we performed a series of control 
experiments, in which PKH2-GL–labeled cells were infused into 
ROSA26 neonatal mice constitutively expressing the LacZ gene 
encoding β-gal. We then searched cardiac tissues for PKH2-GL–
labeled cells that would also express the LacZ transgene but could 
not find any dually stained cells (Figure 7C).
Then, neonatal NMCs were administrated to adult mice. Two 
weeks after injection, PKH2-GL–labeled cells were identified in the 
cardiac muscle (Figure 8A). These cells demonstrated a morphology 
corresponding to that of cardiomyocytes and expressed troponin I 
(Figure 8B). Cardiac precursors from ROSA26 transgenics were also 
infused in WT and FGF-2–deficient mice. These cells were readily 
identified in cardiac tissues by immunostaining as late as 4 weeks 
after injection (Figure 8C), and the expression of LacZ transgene 
was also detected by PCR (Figure 8D).
Discussion
In the present study, we demonstrate that the cardiac NMC popu-
lation contains a subset of cells that express the Sca-1 antigen as 
well as mesenchymal markers and have the capacity to differentiate 
into functional cardiomyocytes. Because these cells do not express 
CD45, CD34, and c-kit, they are reminiscent of skeletal myogenic 
precursors (35). These precursors can home to the heart after injec-
tion into immunocompetent recipient mice and contribute to car-
diac tissues. Interestingly, the differentiation process depends on 
FGF-2, since cells lacking FGF-2 failed to produce mature cardio-
myocytes and stop their differentiation at a precursor stage.
Cell-based therapies to replace lost tissues in the damaged heart 
suggest a promising approach for the treatment of cardiac dis-
eases. Different cell types have been assayed for their capacity to 
differentiate into cardiac myocytes. For instance, spontaneously 
contracting cardiomyocytes can easily be produced from ES cells 
in vitro (36). These cells can even colonize the adult heart and dif-
ferentiate into contractile tissues (37, 38). However, ES cell–derived 
cardiomyocytes resemble cardiac myocytes of the primary heart 
tube (39), and the risk of uncontrolled proliferation of teratoma 
cells, as well as ethical reasons, is likely to reduce their wide use in 
therapies (40, 41). Adult HSCs, as well as stromal stem cells iso-
lated from the bone marrow and endothelial progenitor cells, turn 
into cardiomyocytes under the appropriate culture conditions 
(6–9). Bone marrow cells have even been claimed to differentiate 
into cardiac myocytes in the infarcted area of the heart, where they 
were suggested to contribute to myocardium regeneration (8). 
However, this view has been recently challenged, and it is therefore 
not clear whether bone marrow cells represent a valuable source of 
precursors for cardiac repair (12–14).
Our data demonstrate that the neonatal heart contains a popu-
lation of undifferentiated precursors that can be induced in vitro 
to give rise to functional mature cardiomyocytes. These cells are 
found in the nonmyocyte population of the heart, which includes 
cells derived from the cardiac mesenchyme that result from the 
epithelial-to-mesenchymal transformations (EMTs) taking place 
during heart development (42–44). Transforming cells express the 
transcription factor Snail, which has been suggested to represent 
a marker of epithelial-derived mesenchymal cells in the develop-
ing heart (43, 45). Adoption of a migrative phenotype requires 
the downregulation of adhesion molecules, including cadherins. 
Interestingly, Snail expression appears to be under control of tyro-
sine kinase receptors, including FGFR1, and therefore of FGF-2 
(44, 46). Indeed, cardiac NMCs in the present study concomitant-
ly expressed FGF-2, FGFR1, Snail, and cadherins. Nevertheless, 
culture of NMCs lacking FGF-2 expressed Snail at similar levels 
to those found in WT cells (Figure 2C). It is therefore likely that 
certain redundant pathways, which might involve other FGF fam-
ily members, control Snail expression. Furthermore, EMT in the 
heart requires the presence of TGF-β1 and TGF-β2 (47), which are 
also expressed by cardiac NMCs. During cardiac morphogenesis, 
1 EMT occurs during endocardial cushion formation and cellular-
ization of the cardiac jelly. Interestingly, a second EMT has been 
suggested to involve a subset of epicardial cells that can migrate 
into the myocardium (43). These cells can subsequently differen-
tiate in vitro and in vivo into several cell types, including cardiac 
fibroblasts and cardiomyocytes.
In addition, cardiac NMCs expressed islet-1 after expansion in 
vitro. This transcription factor has been shown to identify cardiac 
progenitors in the developing heart (48, 49). It is noteworthy that 
islet-1 expression is downregulated in differentiating cells, and 
islet-1 could be therefore important in maintaining an undifferen-
tiated state (49). Interestingly, islet-1+ cardioblasts with a capacity 
to differentiate into mature cardiomyocytes were recently demon-
strated to be present in the nonmyocyte fraction of the neonatal 
mouse heart (50). In addition, since adult FGF-2 knockouts do not 
demonstrate cardiac islet-1 expression, this could suggest that the 
heart of adult mice lacking FGF-2 expression is devoid of a par-
ticular cardiac precursor subset. Our data suggest also that precur-
sors in the cardiac NMC population demonstrate mesenchymal 
characteristics, since they appear to be able to produce adipocytes, 
osteoblasts, and skeletal muscle cells in addition to functional car-
diomyocytes. Nevertheless, one cannot exclude at this point that 
these different cell types arise from distinct precursors present in 
the cardiac NMC population.
A significant fraction of cardiac progenitors express Sca-1. 
The percentage of Sca-1+ cells in the neonatal NMC population 
increased during the expansion in vitro. At this point, it is, however, 
difficult to evaluate whether this increase results from proliferation 
of Sca-1+ cells or the conversion of Sca-1– cells. Nevertheless, the 
Figure 6
Factor expression in NMCs. RT-PCR analysis of factor expression in NMCs 
from FGF-2+/+ and FGF-2–/– mice after expansion in vitro (before differentia-
tion) as well as after 3 weeks in control and differentiation medium.
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Sca-1+ cells can produce a cardiogenic progeny under the appro-
priate conditions. Interestingly, Sca-1+ cells are also found in the 
adult heart, and cardiac expression of the Sca-1 antigen is increased 
during hemodynamic overload. However, in our hands, the Sca-1+ 
NMC population from adult mice appeared to present a lesser 
degree of proliferative capacity in vitro than that from neonates. 
Mice lacking Sca-1 expression have been recently described (51). 
Although these animals are viable and grossly normal under basal 
conditions, they suffer from a defect in mesenchymal stem cell self 
renewal, which could be responsible for age-related pathologies (52, 
53). Therefore, it is proposed that Sca-1 could play a role in modify-
ing the balance between self renewal and differentiation.
Recent studies reported the existence of Sca-1+ cardiac precur-
sors in the adult heart (54, 55). Upon cardiac injury, these cells 
were recruited to the damaged area and participated in the 
healing process. These progenitors differ somehow from the 
cells described herein in their expression of particular cell sur-
face markers. In 1 study (54), cardiac progenitors were isolated 
from the adult heart based on Sca-1 expression. Interestingly, 
a significant portion of these cardiac progenitors appeared to 
express high levels of CD31 and CD38, suggesting that they 
might derive from endothelial precursors. In contrast, CD31 
expression is absent on the surface of the WT NMCs described 
in the present study. Then, a Lin–, c-kit+ cell population was 
identified in the adult heart as containing cardiac precursors 
(55). These cells, or their clonal progeny, reconstitute a differ-
entiated myocardium following injection into the border of an 
infarcted ventricular area. Along these lines, the isolation of 
cardiac stem cells from human atrial and ventricular biopsies 
as well as from the adult mouse heart has been reported (56). 
These undifferentiated precursors display self renewal and 
express, for the most part, the c-kit antigen. Only a small frac-
tion of the NMC population in our study appeared to express 
c-kit. In addition, NMCs isolated from W/Wv mice demon-
strate cardiogenic conversion. Interestingly, hearts from W/Wv 
mice were reported to demonstrate a greater capacity to adapt 
to pressure overload than their WT counterparts (57). Indeed, 
whereas ventricular performance decreased gradually in aor-
tic-banded WT mice, decompensation did not occur in W/Wv 
mice. Therefore markers such as Sca-1, c-kit, and islet-1 appear 
to be expressed by cardiac precursors under different condi-
tions. At present, it is possible that all these different cell sub-
sets contribute to maintain precursor pools in the heart and 
might even constitute together the so-called stem cell niches 
within the differentiated tissue.
The differentiation of cardiac precursors into mature car-
diomyocytes appears to be dependent on the capacity of the 
cells to produce FGF-2. The lack of FGF-2 expression does not 
affect the number of precursors in the heart, since the differentia-
tion process can be restored in vitro by the addition of exogenous 
FGF-2, and apoptosis did not appear to be increased in the FGF-2– 
deficient population. On the contrary, Sca-1+ cells accumulate in 
the culture in the absence of FGF-2. Interestingly, some progeni-
tor cells have been shown to express FGFR1 and to be dependent 
on FGF-2 for their expansion (30, 31). Cardiac Sca-1 expression 
in FGF-2 knockouts is revealed during hemodynamic stress (Fig-
ure 1A). In the bone marrow, mesenchymal stem cells, referred to 
also as multipotent adult progenitor cells, express low levels of 
Sca-1 (58). It is therefore possible that, in vivo, in the absence of 
FGF-2, progenitor cells accumulate at an early stage that does not 
express Sca-1. In contrast, after expansion in vitro, a Sca-1+ popula-
tion accumulates in NMCs lacking FGF-2 expression (Figure 2A). 
Figure 7
Cell transfer into neonatal mouse recipients. (A) PKH2-GL–labeled 
cells or cells constitutively expressing the GFP gene under the 
chicken β-actin promoter (GFP) were injected i.v. into neona-
tal mice. Ten days thereafter, heart sections were stained for 
α-actinin. (B) PKH2-GL–labeled FGF-2+/+ or FGF-2–/– NMCs were 
injected into neonatal FGF-2+/+ or FGF-2–/– mice. Ten days after 
injection, heart sections were stained for α-actinin. (C) WT PKH2-
GL–labeled NMCs were injected into neonatal ROSA26 transgenic 
mice, and heart sections were stained for β-gal. Original magnifica-
tion, ×63 (A and C), ×20 (B).
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However, a significant percentage of precursor cells lacking FGF-2 
express CD31, CD34, and Flk-1. This would suggest the accumula-
tion in the culture of cells with a phenotype corresponding to the 
hemangioblast precursor (29).
In any case, these data indicate that the failure to produce FGF-2 
prevents cardiac precursors from completing a normal cardiogenic 
differentiation. This is confirmed in experiments performed in 
vivo, in which differentiation is abolished in the absence of FGF-2 
expression in both the transferred population and the recipient 
animals. Different members of the FGF family, together with other 
proteins such as TGFs or BMPs, have been implicated in cardio-
genesis (28, 59). In particular, FGF-2 appears to be required for 
the expression of cardiac transcription factors and the differentia-
tion of mesoderm explants induced by BMP-2. Moreover, FGF-2 
induces mesenchymal cell formation from precardiac mesoderm 
explants and was shown to stimulate EMT in the epicardium for 
the production of epicardial precursor cells (27, 42, 43, 60). As 
mentioned above, epicardially derived cells were suggested to rep-
resent a source of cardiac stem cells. Nevertheless, mice deficient 
in FGF-2 expression do not suffer from major heart defects during 
embryonic life (21, 61). This suggests that other members of the 
FGF family compensate for the lack of FGF-2 expression in the 
embryo, for instance FGF-4 or FGF-8 (59). This would also indi-
cate that FGF-2 is more important for maintaining cardiac integ-
rity after birth. Alternatively, one cannot exclude that FGF-2 acts 
preferentially on a particular subset of cardiac precursors, which, 
according to our data, would express Sca-1. Interestingly, FGF-2–
deficient mice used in the present study suffer from an impaired 
hypertrophic response and dilated cardiomyopathy (21). Although 
the dilated phenotype was not always observed when independent 
FGF-2 knockouts were used (61), all models are characterized by 
an absence of cardiac remodeling in response to pressure 
overload. Our data provide therefore an attractive hypoth-
esis for explaining this defective cellular response. Finally, 
other factors are likely to play a role in the recruitment, 
survival, and differentiation of cardiac precursors. For 
instance, IGF-1 was recently shown to prevent myocardial 
dysfunction via the preservation of a pool of undifferenti-
ated precursors, which could be mobilized to compensate 
for cardiac cell death (62).
Together, our data provide further evidence that the heart 
contains a population of undifferentiated precursors that 
could be recruited for the production of functional cardio-
myocytes. These cardiac precursors are probably derived 
from a mesodermal population with characteristics of 
mesenchymal and/or hemangioblast precursors. Impor-
tantly, the differentiation process requires the presence of 
FGF-2. Several clinical trials have been launched to evaluate the 
therapeutic potential of FGF-2 in cardiac diseases (22–25). In par-
ticular, FGF-2 is currently tested as a drug capable of stimulating 
revascularization for the treatment of chronic ischemic conditions. 
Our results suggest that the beneficial effects of FGF-2 could extend 
beyond its angiogenic actions. Indeed, FGF-2 could participate in 
the self regeneration of the heart by accelerating the mobilization 
and differentiation of resident stem cells for cardiac repair.
Methods
Mice. Neonatal C57BL/6 mice (Charles River Laboratories) were used 
as a source of NMCs. Adult and neonatal mice lacking FGF-2 (21) 
maintained on a C57BL/6 background, transgenic mice bearing the 
LacZ reporter gene [129S7-Gt(ROSA)26Sor; Jackson Laboratory] or the 
chicken β-actin–GFP reporter (63), and W/Wv mice (deficient in c-kit sig-
naling) (33, 34) were used in some experiments. Animals were handled 
according to institutional guidelines after approval from the State Vet-
erinary Office (Lausanne, Switzerland).
Cell culture and cardiogenic differentiation. Cardiac NMCs were isolated as 
previously described (21). Briefly, ventricles were digested in buffer contain-
ing 0.45 mg/ml collagenase (Worthington Biochemical Corp.) and 1 mg/ml 
pancreatin (Invitrogen Corp.). Cardiomyocytes and NMCs were separated by 
differential plating (45 minutes), and expanded in culture in a 3:1 mixture of 
DMEM and Medium 199 (Invitrogen Corp.) supplemented with 10% horse 
serum (Serotec), 5% FBS (Serotec), 100 U/ml penicillin G, and 100 µg/ml 
streptomycin. After 2 passages, cells were switched to a differentiation medi-
um composed of MEM Alpha (Invitrogen Corp.), 10% FBS, and supplemented 
with 1 µM dexamethasone (Sigma-Aldrich), 50 µg/ml ascorbic acid (Sigma-
Aldrich), and 10 mM β-glycerophosphate (Sigma-Aldrich). Control medium 
was MEM plus FBS. In some cases, media were supplemented with 25 ng/ml 
FGF-2 (R&D Systems) or FGF-1 (Upstate) for 4 or 10 days, respectively.
Figure 8
Cell transfer into adult mouse recipients. (A) PKH2-GL–labeled 
cells isolated from WT hearts were injected into adult FGF-2+/+ 
mice. Original magnification. (B) Troponin I expression of differ-
entiated precursors in WT recipient hearts. Two weeks after cell 
transfer, heart sections were stained for α-actinin. (C) NMCs 
isolated from ROSA26 transgenic mice were injected into adult 
FGF-2+/+ mice. Sections were immunostained for β-gal 4 weeks 
after transfer. (D) RT-PCR analysis of LacZ gene expression in 
hearts from FGF-2+/+ and FGF-2–/– mice after transfer of NMCs 
from ROSA26 transgenic mice (Transferred). None, no cells 
transferred. Magnification, ×20 (A), ×100 (B), ×40 (C).
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Differentiation into other cell types. For inducing differentiation into adi-
pocytes, osteoblasts, and skeletal myocytes, NMCs were incubated in the 
following media, respectively: MEM/FBS containing 1 µM dexamethasone, 
0.5 mM 3-isobutyl-1-methylxanthine, and 5 µg/ml insulin; MEM/FBS con-
taining 1 µM dexamethasone, 50 µg/ml ascorbic acid, 10 mM β-glycero-
phosphate, and 10 nM 1-α,25-dihydroxyvitamin D3; MEM/FBS containing 
1.5 µg/ml amphotericin B.
RT-PCR. Total RNA was extracted from either cultured cells or cardiac tis-
sues (RNeasy Mini Kit; QIAGEN), reverse-transcribed (30 minutes, 55°C), 
and amplified by PCR (OneStep RT-PCR kit; QIAGEN). Primers and opti-
mal annealing temperatures are listed in Supplemental Table 1. PCR prod-
ucts were run on a 2% NuSieve GTG agarose gel (Cambrex Corp.).
Immunohistochemistry. For immunostaining, NMCs were fixed with 4% 
paraformaldehyde in PBS, and permeabilized with 0.2% Triton X-100 in 
PBS. Cells were incubated with antibodies directed to sarcomeric α-actinin 
(Sigma-Aldrich), osteocalcin (ANAWA Trading SA), Sca-1 (BD Biosciences), 
troponin I-C, vWF (factor VIII), and MyoD1 (all from Santa Cruz Biotech-
nology Inc.). Fluorophore-conjugated secondary antibodies were as follows: 
FITC-labeled anti-mouse IgG, anti-rabbit IgG, and anti-goat IgG (all from 
Sigma-Aldrich). Antibodies were diluted in PBS containing 1% nonimmune 
goat serum (Sigma-Aldrich) or BSA (Sigma-Aldrich). DNA was stained 
with DAPI (Invitrogen Corp.). Heart cryosections from neonatal and adult 
mice were fixed with 4% paraformaldehyde and stained with either a rat 
anti–Sca-1 (BD Biosciences), a mouse anti–α-actinin (Sigma-Aldrich), a 
mouse anti–β-gal (Sigma-Aldrich), or a goat anti–troponin I-C (Santa Cruz 
Biotechnology Inc.). The appropriate secondary antibodies were coupled 
with Alexa 488 or Alexa 594 fluorochrome (Invitrogen Corp.). Slides were 
mounted with FluorSave reagent (Merck Biosciences) and examined with 
a Carl Zeiss Axiophot I microscope equipped with an AxioCam color CCD 
camera (Carl Zeiss). For oil red staining, cells were washed 3 times with PBS 
and fixed for 4 minutes in 3.7% formaldehyde. Oil red O (0.5% in isopropa-
nol; Sigma-Aldrich) was diluted 4 times in H2O, and added to the cells for 1 
hour at room temperature.
FACS. Cells were resuspended in PBS containing 3% FBS and 2 mM 
EDTA, and labeled with various antibodies for 30 minutes on ice. Anti-
bodies used in this study were cyanine 5 (Cy5) anti–mouse Ly-6A/E 
(Sca-1) (eBioscience), FITC anti-CD45, PE anti-CD117, PE anti–c-kit, PE 
anti-CD34, PE anti–Flk-1, FITC anti-CD3, and FITC anti-B220. In some 
experiments, cells were incubated with rat antibodies directed against 
Gr-1, Mac-1, CD31, and TER119 and a FITC-labeled anti-rat antibody of 
goat origin (all from BD Biosciences). In some experiments, suspensions 
were depleted of cells expressing CD45, CD31, CD34, Flk-1, CD3, CD4, 
CD8, B220, TER119, Mac-1, and Gr-1 following incubation with specific 
rat antibodies directed against mouse proteins and anti-rat magnetic 
beads (Dynabeads; Dynal Biotech).
Apoptosis assay. Cells were UV-irradiated (positive control), or main-
tained in either control or differentiation medium, and stained for 15 
minutes with Hoechst 33342 (10 µg/ml). Then, the number of damaged 
nuclei was determined.
Cell transfer. Undifferentiated NMCs from WT, β-actin–GFP, or ROSA26 
mice were isolated from neonatal hearts, and expanded in culture. WT 
NMCs were labeled with membrane dye PKH2-GL (Sigma-Aldrich; 
4 × 10–6 M, 5 minutes, room temperature). Cells (105 in 100 µl PBS, 2 mM 
EDTA) were injected into neonatal mice through the superficial temporal 
vein. Cells (6 × 105 in 600 µl PBS, 2 mM EDTA) were injected into adult 
mice via the tail vein. Cellular engraftment was determined 1 week or 2 
weeks after transfer in neonatal mice and adult mice, respectively. Reno-
vascular hypertension (2-kidney 1-clip model) was produced in adult mice 
as previously described (32).
Statistical analysis. One-way ANOVA was used to test for differences 
between groups. P values of less than 0.05 were considered significant.
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